Trial Profile
Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A Prospective Randomized Multicenter Study comparing Thrombopoetin-Receptor agonist Eltrombopagwith Placebo in Patients with Acquired Moderate Aplastic Anemia who are treated with Ciclosporin A
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Aplastic anaemia
- Focus Therapeutic Use
- Acronyms EMAA
- 31 Mar 2020 Planned number of patients changed from 116 to 90.
- 13 Feb 2015 New trial record